First Time Loading...

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 1.15 USD -1.71% Market Closed
Updated: May 15, 2024

Adaptimmune Therapeutics PLC
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptimmune Therapeutics PLC
Interest Income Expense Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Interest Income Expense
$6m
CAGR 3-Years
35%
CAGR 5-Years
73%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Interest Income Expense
$570k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Interest Income Expense
-$29m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Interest Income Expense
$13.4m
CAGR 3-Years
N/A
CAGR 5-Years
126%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Interest Income Expense
-£344k
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Interest Income Expense
-£10.1m
CAGR 3-Years
N/A
CAGR 5-Years
-102%
CAGR 10-Years
-20%

See Also

What is Adaptimmune Therapeutics PLC's Interest Income Expense?
Interest Income Expense
6m USD

Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Interest Income Expense amounts to 6m USD.

What is Adaptimmune Therapeutics PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
73%

Over the last year, the Interest Income Expense growth was 287%. The average annual Interest Income Expense growth rates for Adaptimmune Therapeutics PLC have been 35% over the past three years , 73% over the past five years .